XERS – xeris biopharma holdings, inc. (US:NASDAQ)
Stock Stats
News
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
Xeris Biopharma (NASDAQ:XERS) had its price target raised by analysts at Piper Sandler from $6.00 to $8.00. They now have a "neutral" rating on the stock.
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Form 4 Xeris Biopharma Holdings For: Dec 01 Filed by: Hecht Beth
Form 8-K Xeris Biopharma Holdings For: Dec 01
Form 4 Xeris Biopharma Holdings For: Nov 13 Filed by: Shannon John Patrick Jr
Form 4 Xeris Biopharma Holdings For: Nov 11 Filed by: Hecht Beth
Form 144 Xeris Biopharma Holdings Filed by: Hecht Beth
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.